Merck & Co.
213 E Grand Avenue, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA 02141
United States
4223 articles about Merck & Co.
-
FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
9/19/2023
Merck, known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration has accepted and granted priority review for a supplemental new drug application seeking approval for WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, for the treatment of adult patients with advanced renal cell carcinoma following immune checkpoint and anti-angiogenic therapies.
-
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA® (pembrolizumab)
9/19/2023
1ST Biotherapeutics, Inc. announced a Clinical Trial Collaboration and Supply Agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to evaluate FB849 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® in a Phase I/II clinical trial for the treatment of patients with advanced solid tumors.
-
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
9/15/2023
Merck (NYSE: MRK) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of adults with non-small cell lung cancer (NSCLC), who are at high risk of recurrence following complete resection and platinum-based chemotherapy.
-
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
9/11/2023
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck’s novel investigational activin signaling inhibitor biologic, for adults with pulmonary arterial hypertension (PAH) (WHO Group 1) at the European Respiratory Society (ERS) International Congress 2023.
-
BioInvent initiates subcutaneous arm of Phase 1/2 trial with BI-1206 in solid tumors
9/8/2023
BioInvent International AB announces the enrollment of the first patient in a Phase 1/2 trial in combination with KEYTRUDA®, MSD's anti-PD-1 therapy, investigating a subcutaneous formulation of its lead drug candidate, the novel anti-FcyRIIB antibody BI-1206, in solid tumors.
-
European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
9/7/2023
Merck, known as MSD outside of the United States and Canada, announced that the European Commission has approved an expanded indication for ERVEBO for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease caused by Zaire ebolavirus.
-
Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
9/5/2023
Merck announced that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11, 2023, at 2:15 p.m. EDT.
-
Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics
9/5/2023
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced new, 10-year long-term follow-up (LTFU) data published in the peer reviewed journal, Pediatrics, for girls and boys who received a three-dose regimen of GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) at 9-15 years old.
-
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors
9/5/2023
Portage Biotech Inc. today announced that it has entered into a clinical trial collaboration agreement with Merck to evaluate Portage’s next-generation adenosine antagonists in combination with KEYTRUDA ® (pembrolizumab).
-
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
8/29/2023
Merck, known as MSD outside of the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor receptor 2 -positive gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1.
-
Merck to Participate in the Citi 18th Annual BioPharma Conference
8/29/2023
Merck, known as MSD outside of the United States and Canada, announced that Dr. Marjorie C. Green, senior vice president and head of late-stage oncology, Global Clinical Development, is scheduled to participate in a fireside chat at the Citi 18th Annual BioPharma Conference on Wednesday, Sept. 6, 2023, at 1:50 p.m. EDT.
-
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
8/25/2023
Merck, known as MSD outside of the United States and Canada, announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral proprotein convertase subtilisin/kexin type 9 inhibitor, being evaluated for the treatment of adults with hypercholesterolemia.
-
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
8/25/2023
Merck, known as MSD outside of the United States and Canada, and Eisai provided an update on the Phase 3 LEAP-010 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma whose tumors express PD-L1.
-
While an initial analysis showed improvements in progression-free survival and objective response rate, a second analysis saw no improvement in overall survival.
-
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
8/24/2023
AstraZeneca and Merck, known as MSD outside of the United States and Canada, announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone has been approved in Japan for the treatment of adult patients with BRCA-mutated castration-resistant prostate cancer with distant metastasis.
-
Many products are facing the loss of their patents or exclusivity clauses. Here’s what to expect in the coming months.
-
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
8/18/2023
Merck, known as MSD outside of the United States and Canada, announced topline results from LITESPARK-005, the first positive Phase 3 trial investigating WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor.
-
The company is continuing its renal cell carcinoma push for its oral HIF-2α inhibitor Welireg with promising Phase III data showing significant progression-free survival improvements in patients.
-
Merck Is Harnessing Innovation To Reach Indigenous Communities
8/8/2023
Merck & Co., Inc. - Alaska is a vast state with extremes in weather and terrain.
-
Ginkgo Bioworks Announces Collaboration with Merck to Improve Biologic Manufacturing
8/7/2023
Ginkgo Bioworks today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, focused on improving biologic manufacturing.